Ignite Creation Date:
2025-12-24 @ 2:46 PM
Ignite Modification Date:
2026-05-09 @ 2:45 AM
Study NCT ID:
NCT06578559
Status:
RECRUITING
Last Update Posted:
2025-04-18
First Post:
2024-07-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
Sponsor:
Gruppo Oncologico del Nord-Ovest
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
BRICKET
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None